Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Trial of Talimogene Laherparepvec in Combination With Dabrafenib and Trametinib in Advanced Melanoma With an Activating BRAF Mutation

NCT03088176 is registered in ClinicalTrials.gov with West Cancer Center as lead sponsor.

NCT NCT03088176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03088176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Trial of Talimogene Laherparepvec in Combination With Dabrafenib and Trametinib in Advanced Melanoma With an Activating BRAF Mutation
Lead sponsor
West Cancer Center
Phase
Phase 1
Overall status
Unknown status
Start date
June 25, 2017
Completion date
June 30, 2021
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf gene mutation, melanoma